Osaka Study for COVID-19 vaccine at Geriatric facilities
- Conditions
- none
- Registration Number
- JPRN-jRCT1051200148
- Lead Sponsor
- akata Hiroyuki
- Brief Summary
After the second dose, geometric mean titers (GMT) of anti-RBD with both the Abbott and Roche assay were significantly lower in residents than staff (GMT for Abbott assay: residents 2282 AU/mL vs staff 8505 AU/mL; that for Roche assay: residents 258 U/mL vs staff 948 U/mL). Multivariate analysis of characteristics affecting antibody responses (>1280 AU/mL for Abbott and >210 U/mL for Roche) showed lower odds ratios for older age, steroid usage and NSAID usage.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 255
1. Residents and staffs at Osaka geriatric intermediate care facilities who wish to receive COVID-19 vaccine
2. Those who can follow the study schedule during the follow-up period
3. Written informed consent
1. Those who have a condition under the contraindications for vaccination
2. Those who are judged to be inappropriate as study subjects by the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method immunogenicity
- Secondary Outcome Measures
Name Time Method effectiveness, side effects after vaccination, vaccine associatd adverse events, immunogenicity based on the neutralizing antibody